Sign in
Knowstox

Fundamentals snapshot

Agenus Inc.

AGEN · NCM · Healthcare · Biotechnology

Current price

$7.22

52-week range

$2.71 - $10.31

Market cap

$326.68M

One-glance verdict

Not enough data

Fair value unavailable

Not enough cash-flow history to value this one with our method.

Balance sheet

Healthy

-0.37x Concerning

Net cash $47.47M. Interest coverage shows how many times profit covers the interest bill.

What this company does

Agenus Inc.

Agenus Inc. develops new medicines to help the body fight cancer and infections. Their main focus is creating treatments that use the body's own immune system, and they make money through selling these treatments or partnering with larger drug companies. This matters because successful treatments could help many patients and make the company more valuable.

Price history

How the share price has moved

—
Loading price history…

Earnings history

Last 8 quarters — what happened

Click any quarter to read the call summary and what the numbers say.

Free cash flow by quarter (oldest to newest)
FY2024 Q4 $-28.73M FY2025 Q1 $-25.62M FY2025 Q2 $-20.22M FY2025 Q3 $-14.74M FY2025 Q4 $-16.62M FY2026 Q1 $-35.95M FY2026 Q2 $-31.20M FY2026 Q3 $-20.09M
Revenue $31.49M
Net income —
Diluted EPS 0.02
Operating cash flow $-20.09M
Free cash flow $-20.09M
Revenue $34.52M
Net income —
Diluted EPS -0.01
Operating cash flow $-31.20M
Free cash flow $-31.20M
Revenue $33.74M
Net income —
Diluted EPS 1.02
Operating cash flow $-35.95M
Free cash flow $-35.95M
Revenue $34.20M
Net income —
Diluted EPS 0.09
Operating cash flow $-16.62M
Free cash flow $-16.62M
Revenue $30.23M
Net income —
Diluted EPS 1.94
Operating cash flow $-14.74M
Free cash flow $-14.74M
Revenue $25.69M
Net income —
Diluted EPS -1.00
Operating cash flow $-20.22M
Free cash flow $-20.22M
Revenue $24.07M
Net income —
Diluted EPS -1.03
Operating cash flow $-25.62M
Free cash flow $-25.62M
Revenue $26.84M
Net income —
Diluted EPS -1.95
Operating cash flow $-28.65M
Free cash flow $-28.73M

Is it cheap or expensive?

Fair value — vs current price $7.22

We couldn't calculate a fair value right now.

lower confidence

We estimate the cash this business should generate over the next 10 years and beyond, then convert it to today's money for a fair value per share, in its trading currency. Cautious, middle and optimistic growth cases give a range. Not for banks/insurers.

Is it drowning in debt?

Healthy

Net cash $47.5M - more cash than debt. Interest coverage -0.4x.

Net debt $-47.47M
Interest coverage -0.37x
Healthy
Worse cushion Baseline Better cushion
AGEN BASELINE Agenus Inc.

Total debt $39.46M Interest coverage -0.37x This is the baseline the peer rows are being compared against.

-0.37x

What you should know

The case for and against AGEN

1 Reward 0 Risks

Rewards

  • Revenue grew 17.3% last year.

Risks

The numbers

All the key metrics, grouped by purpose

Tap any ? icon to learn what it means.

Valuation

How expensive the stock looks

P/E (TTM)
31.39x
Forward P/E
-45.12x
P/B
-3.10x
P/S
2.44x
EV/EBITDA
5.02x
PEG ratio
1.44x

Profitability

How much profit each dollar creates

Gross margin
122.9%
Operating margin
38.9%
Net margin
30.8%
ROE
—
ROA
13.6%

Health

Liquidity and balance-sheet strength

Debt / equity
—
Current ratio
0.73x
Quick ratio
0.70x
Total debt
$39.46M
Total cash
$86.94M

Growth

How the business has been compounding

Revenue TTM
$133.95M
Revenue 5Y CAGR
-21.2%
EPS TTM
0.23
EPS 5Y CAGR
—

Cash flow

How much cash the business throws off

Operating CF TTM
$-103.86M
Free CF TTM
$-77.20M
FCF margin
-57.6%

Dividend

Shareholder payout

Yield
0.0%
Payout ratio
0.0%
Last ex-div date
—